Pricing Log in Create free account

Arrowhead Pharmaceuticals, Inc. (ARWR) vs Caris Life Sciences,�Inc. (CAI)

Arrowhead Pharmaceuticals, Inc. and Caris Life Sciences,�Inc. are both Biotechnology companies. Arrowhead Pharmaceuticals, Inc. is the larger, with a market value of $8.1B against $7.4B — 1.1× the size. Arrowhead Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 77.7×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 68.8% against 16.1%. Caris Life Sciences,�Inc. has the higher net margin (9.16% vs −47.8%) and the higher return on invested capital (22.2% vs 0.00%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 14 and Arrowhead Pharmaceuticals, Inc. on 3.

Valuation

Metric ARWR CAI Biotechnology median
P/E n/m 77.71 10.26
P/S 12.34 7.15 9.18
P/B 17.73 12.66 2.05
Price to free cash flow n/m 190.71 24.81
EV/EBITDA n/m 39.40 0.65
EV/Sales 11.24 6.77 8.98
Earnings yield (3.90%) 1.29% (34.89%)
Free cash flow yield (0.91%) 0.52% (24.52%)

Profitability

Metric ARWR CAI Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (33.82%) 13.35% 0.00%
Net margin (47.79%) 9.16% 0.00%
Free cash flow margin (11.22%) 8.00% 0.00%
Return on equity (64.91%) 0.00% (50.12%)
Return on assets (18.32%) 8.58% (45.60%)
Return on invested capital 0.00% 22.24% 0.00%

Growth

Metric ARWR CAI Biotechnology median
Revenue growth (TTM) 16.13% 68.84% 6.26%
EPS growth (last fiscal year) 99.80% 69.79% 29.88%
Revenue growth, 5-year CAGR 56.63% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ARWR CAI Biotechnology median
Debt to equity 1.85 0.00 0.00
Current ratio 5.90 6.71 4.89
Net debt to EBITDA (5.70) (5.23) 1.01

Dividend

Metric ARWR CAI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARWR CAI Biotechnology median
Market cap 8.12b 7.36b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack